首页> 外文期刊>Current hypertension reports. >Does remission of renal disease associated with antihypertensive treatment exist?
【24h】

Does remission of renal disease associated with antihypertensive treatment exist?

机译:是否存在与降压治疗相关的肾脏疾病缓解?

获取原文
获取原文并翻译 | 示例
           

摘要

In diabetic and nondiabetic chronic nephropathies, high blood pressure and urinary loss of proteins represent major determinants of progressive renal function decline. Reducing blood pressure with drugs that inhibit the renin-angiotensin system also lowers glomerular hypertension and ameliorates glomerular sieving properties, thus reducing proteinuria. Reducing urinary protein levels with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor antagonists (ARA) limits renal function decline to the point that remission of disease and regression of renal lesions have been observed in experimental animals and in humans. This therapy, however, may not be effective in all patients. For patients who do not achieve complete remission of proteinuria, renoprotective treatment should include intensified blood pressure control (and metabolic control in diabetes) and amelioration of dyslipidemia. Early intervention, before progressive glomerulosclerosis and scarring is initiated by increased protein traffic, may be important to maximize reno- and cardioprotection, especially in diabetes.
机译:在糖尿病和非糖尿病慢性肾病中,高血压和尿蛋白的丢失是进行性肾功能下降的主要决定因素。用抑制肾素-血管紧张素系统的药物降低血压,还可以降低肾小球高血压和改善肾小球筛分特性,从而减少蛋白尿。使用血管紧张素转换酶抑制剂(ACEi)或血管紧张素II受体拮抗剂(ARA)降低尿蛋白水平可将肾功能下降限制在这样的程度,即在实验动物和人类中均已观察到疾病的缓解和肾损害的消退。但是,这种疗法可能并非对所有患者都有效。对于不能完全缓解蛋白尿的患者,肾脏保护治疗应包括加强血压控制(以及糖尿病的代谢控制)和血脂异常的改善。在进行性肾小球硬化和瘢痕形成(由蛋白质运输增加引起)之前进行早期干预,对于最大化肾脏和心脏保护(特别是在糖尿病中)可能是重要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号